Table of Contents for Stem Cell Therapies and Regenerative Medicine: Current Applications and Future Possibilities
INTRODUCTION XVI
REASON FOR DOING THE STUDY XVI
STUDY GOAL AND OBJECTIVES XVI
CONTRIBUTIONS OF THE STUDY AND FOR WHOM XVII
SCOPE AND FORMAT XVII
METHODOLOGY AND INFORMATION SOURCES XVIII
ANALYST'S CREDENTIALS XVIII
OTHER RELEVANT BCC REPORTS AND PUBLICATIONS XIX
BCC ONLINE SERVICES XX
DISCLAIMER XX
SUMMARY XXI
Summary Table:
GLOBAL FORECAST OF REVENUES FOR STEM CELL AND CYTOKINE THERAPIES IN REGENERATIVE MEDICINE, THROUGH 2010 ($ BILLIONS) XXII
Summary Figure:
GLOBAL FORECAST OF REVENUES FOR STEM CELL AND CYTOKINE THERAPIES IN REGENERATIVE MEDICINE, 2003-2010 ($ BILLIONS) XXIII
OVERVIEW 1
Table 1 PERCENT OF PERSONS USING PRESCRIPTION DRUGS IN THE PAST MONTH IN THE U.S., 1999-2000 1
GROWTH FACTORS AND CYTOKINES 1
Table 2 SELECTED CYTOKINES OR GROWTH FACTORS RELEVANT TO REGENERATIVE MEDICINE 2
Table 2 (CONTINUED) 3
STEM AND PROGENITOR CELLS 3
WORLDWIDE MARKETS FOR REGENERATIVE MEDICINE 4
Table 3 LEADING CAUSES OF DEATH IN THE U.S., 2001 5
Table 4 PREVALENCE OF MEDICAL CONDITIONS IN THE U.S. WITH POTENTIAL CELL THERAPIES 6
Table 5 AGING OF THE U.S. POPULATION 6
CELL THERAPIES AS A SUBSTITUTE FOR TRANSPLANTS 7
THE U.S. MARKET VERSUS THE REST OF THE WORLD 7
The U.S. Market versus the (Continued) 8
Table 6 POPULATION OF COUNTRIES OF THE EUROPEAN UNION, 2003 9
DISTRIBUTION OF REVENUES AND EFFORT 10
TYPES OF STEM OR PROGENITOR CELLS 11
Table 7 DESCENDANTS OF THE HUMAN MESENCHYMAL STEM CELL 12
Autologous Cells 13
Allogeneic Cells 14
UMBILICAL CORD BLOOD 14
Table 8 A PARTIAL LIST OF DISEASES TREATED USING CORD BLOOD STEM CELLS 15
EMBRYONIC STEM CELLS 16
Embryonic Stem Cells (Continued) 17
Table 9 DERIVATION OF BODY TISSUE TYPES FROM GERM LAYERS 18
Table 10 CELL TYPES DERIVED FROM EMBRYONIC STEM CELLS IN VITRO 18
Table 10 (CONTINUED) 19
Identification of Stem Cells 19
Table 11 MARKERS OF PLURIPOTENT CELLS IN MOUSE, MAN, AND MONKEY 20
Therapeutic Cloning 20
Therapeutic Cloning (Continued) 21
Utility of ES Cells 22
Ethical Considerations 23
Position of the Catholic Church 24
Position of the National Academy of Sciences 25
Politics and Funding for Embryonic Stem Cell Research 26
Politics and Funding for Embryonic Continued) 27
NIH Guidelines 28
NIH Guidelines (Continued) 29
Table 12 EMBRYONIC STEM CELL LINES THAT MEET NIH FUNDING REQUIREMENTS, WHICH ARE AVAILABLE FOR SHIPPING 30
Patents 30
GERM CELLS 31
WHAT MAKES A STEM CELL A STEM CELL? 31
CELL-BASED GENE THERAPY 32
U.S. REGULATION 33
DEVICES 33
Table 13 FOOD AND DRUG ADMINISTRATION BODIES INVOLVED IN IMPLANT REGULATION 34
BIOLOGICALS 35
Biologicals (Continued) 36
ORPHAN PRODUCT STATUS 37
INTERNATIONAL ISSUES 37
OFFSHORE CELL-THERAPY TREATMENTS 38
OFFSHORE CELL-THERAPY TREATMENTS (CONTINUED) 39
APPLICATIONS FOR PROGENITOR CELL THERAPIES 40
APPLICATIONS OF REGENERATIVE MEDICINE FOR BLOOD AND THE IMMUNE SYSTEM 40
Figure 1 HEMATOPOIESIS 41
APPLICATIONS OF REGENERATIVE CONTINUED) 42
Table 14 A PARTIAL LIST OF DISEASES TREATED WITH HEMATOPOIETIC STEM CELLS 43
Table 14 (CONTINUED) 44
HARVESTING HEMATOPOIETIC STEM CELLS 44
Bone Marrow 44
Peripheral Blood Progenitor Cell Collection 45
Umbilical Cord Blood 46
Drug-Resistant Hematopoietic Stem Cells 46
PRODUCTS AND SERVICES IN SUPPORT OF HEMATOPOIETIC STEM CELL TRANSFERS 47
Table 15 COMMERCIAL OPPORTUNITIES FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION 48
CYTOKINES FOR STEM CELL THERAPY 49
Table 16 APPROVED BIOPHARMACEUTICALS FOR THE REGENERATION OF BLOOD AND IMMUNE CELLS AFTER CHEMOTHERAPY 50
G-CSF and GM-CSF 50
AMD3100 51
Erythropoietins 51
MARKET OPPORTUNITIES FOR REGENERATIVE CYTOKINES 52
Table 17 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, THROUGH 2010 ($ MILLIONS) 53
Figure 2 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, 2003-2010 ($ MILLIONS) 53
HARVESTING AND STORAGE OF UMBILICAL CORD BLOOD 54
Table 18 COMMERCIAL UMBILICAL CORD BLOOD STORAGE COMPANIES 55
Market Opportunities for Umbilical Cord Blood Storage 56
Table 19 FEES CHARGED BY MAJOR UMBILICAL CORD BLOOD BANKS, 2005 ($) 57
Table 20 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, THROUGH 2010 ($ MILLIONS) 58
Figure 3 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, 2003-2010 ($ MILLIONS) 58
EXPANSION OF STEM CELLS 58
Expansion of Stem Cells (Continued) 59
Market Opportunities for Stem Cell Expansion. 60
Table 21 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, THROUGH 2010 ($ MILLIONS) 60
Figure 4 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, 2003-2010 ($ MILLIONS) 61
GRAFT-VERSUS-HOST DISEASE 61
IMMUNE DEFICIENCIES 62
Acquired Immunodeficiency Syndrome 63
Table 22 AQUIRED IMMONDEFICIENCY CASES REPORTED BY YEAR IN THE U.S., 1985-2003 64
Natural Resistance 64
Current Therapies for AIDS 65
Progenitor Cell Therapies for AIDS 65
Market Opportunities for AIDS Therapies 66
Table 23 SIZE OF THE AIDS/HIV EPIDEMIC 66
SUMMARY: BLOOD AND IMMUNE DISEASES 67
Table 24 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS) 67
Table 5 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS) 68
SKIN 68
SKIN CELL PROGENITORS 69
BURNS 69
ULCERS 70
ULCERS (CONTINUED) 71
MARKET OPPORTUNITIES FOR SKIN CELL THERAPIES 72
MARKET OPPORTUNITIES FOR SKIN CELL THERAPIES (CONTINUED) 73
Table 25 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, THROUGH 2010 ($ MILLIONS) 74
Figure 6 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, 2003-2010 ($ MILLIONS) 74
BONE 74
BONE FRACTURES 75
Bone Metabolism 76
Current Therapies 77
Cell Therapies for Bone Fractures 77
Growth Factors and Morphogenic Proteins 78
Table 26 GROWTH FACTOR PRODUCTS FOR BONE HEALING 79
Table 27 GROWTH FACTORS DEVELOPED BUT NOT YET APPROVED FOR BONE INDICATIONS 80
Market Opportunities for Regenerative Therapies for Fractures and Spinal Fusions 80
Table 28 SPINAL FUSION DATA, U.S. 1998-2002 ($) 81
Table 29 NUMBER OF LOWER LEG FRACTURE, 1998-2002 81
Table 30 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS) 82
Figure 7 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS) 82
CARTILAGE 83
Table 31 PRODUCTS FOR REGENERATIVE CARTILAGE REPAIR 83
MENISCUS REPAIR 83
INJURIES OF THE KNEE 84
INTERVERTEBRAL DISC REGENERATION 85
MARKETS FOR CARTILAGE REPAIR 85
Table 32 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, THROUGH 2010 ($ MILLIONS) 86
Figure 8 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, 2003-2010 ($ MILLIONS) 87
CARDIOVASCULAR SYSTEM 87
CONGESTIVE HEART FAILURE 88
Current Therapies 88
CORONARY HEART DISEASE 89
Current Therapies 89
CELL THERAPIES FOR CHF OR CORONARY DISEASE 89
Cell Therapies for CHF or Coronary Disease (Continued) 90
Cell Therapies for CHF or Coronary Disease (Continued) 91
CARDIAC ARRYTHMIA 92
Current Therapy 92
Cell Therapies 93
MARKET OPPORTUNITIES FOR CARDIOVASCULAR CELL THERAPIES 93
Table 33 PREVALENCE OF HEART DISEASE IN U.S. ADULTS (18 YEARS AND OVER), 2002 (THOUSAND) 94
TEETH 95
HAIR 95
BRAIN AND NERVOUS SYSTEM 96
NEURAL STEM CELLS 97
LYSOSOMAL STORAGE DISEASES 97
DISORDERS OF THE MYELIN SHEATH 98
SPINAL CORD INJURY 99
Spinal Cord Injury (Continued) 100
STROKE 101
Table 34 DEATH RATES PER 100,000 FROM CEREBROVASCULAR DISEASE (STROKE) IN THE U.S., 1960 AND 2002 102
PARKINSON'S DISEASE 103
Cell Therapies 103
Cell Therapies (Continued) 104
The Market Opportunities for Regenerative Treatments to Treat Neural Disease 105
EYES 105
EYES (CONTINUED) 106
Market Opportunities 107
LIVER 108
HUMAN CELL THERAPIES 109
Human Cell Therapies (Continued) 110
Markets for Regenerative Therapies for the Liver 111
KIDNEY 111
Potential Cell Therapies for Kidney Disease 112
Market Opportunities for Regenerative Kidney Therapies 113
DIABETES 113
Table 35 GLOBAL PREVALENCE OF DIABETES IN EUROPE, AGES 20 TO 79 2003 AND 2025 (THOUSANDS) 114
COMPLICATIONS OF DIABETES 115
Current Treatments 115
Edmonton Protocol 116
STEM CELL THERAPIES 116
Market Opportunities for Regenerative Diabetes Therapies 117
REPRODUCTIVE MEDICINE 118
MARKET OPPORTUNITIES FOR OOCYTE CRYOPRESERVATION 119
Table 36 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, THROUGH 2010 ($ MILLION) 120
Figure 9 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, 2003-2010 ($ MILLION) 120
PRODUCTS USED IN CELL THERAPY AND REGENERATIVE MEDICINE 121
PRODUCTS USED FOR AMPLIFYING, CULTURING, OR TRANSFERRING STEM CELLS 121
AASTROMREPLICELL SYSTEM 121
MYOCATH PERCUTANEOUS DELIVERY SYSTEM 122
PLURIX BIOREACTOR SYSTEM 123
CYTOMATRIX 123
CYTOKINES AND GROWTH FACTORS 124
Table 37 CYTOKINES AND GROWTH FACTORS IN REGENERATIVE MEDICINE 124
AMD3100 125
ARANESP 125
BMP-7 126
CHRYSALIN 126
CTCE-0214 126
CYT 99 007 127
EPOGEN/PROCRIT 127
INFUSE/INDUCTOS 128
NEULASTA 128
NEUMEGA 129
NEUPOGEN 129
OP-1 130
REGRANEX GEL 131
THYMOSIN BETA FOUR 131
TUMOR GROWTH FACTOR ALPHA 132
LIVING CELL THERAPIES 132
HEMATOPOIETIC AND IMMUNE CELL THERAPIES 133
Table 38 LIVING BLOOD AND IMMUNE CELL THERAPEUTIC PRODUCTS IN DEVELOPMENT 133
Highly Purified Hematopoietic Stem Cells 134
HGTV-43 134
MP Cells 135
Procord 136
SKIN 136
Table 39 LIVING SKIN EQUIVALENTS USED THERAPEUTICALLY 136
Apligraf 137
Dermagraft 137
EpiCel 138
Hyalograft 3D 138
Laserskin Autograft 138
OrCel 139
CARTILAGE 139
Table 40 LIVING-CELL PRODUCTS USED THERAPEUTICALLY TO REPAIR CARTILAGE 139
Carticel 139
Cartilink 140
Chondrogen 141
Co.Don Chondrotransplant 141
Co.Don Chondrotransplant DISC 141
Hyalograft C 142
ICX-PRO 142
ICX-SKN 142
NEURAL STEM CELLS 143
HuCNS-SC 143
MUSCLE 143
Table 41 MUSCLE CELLS USED AS THERAPEUTIC PRODUCTS 143
Biopace 143
MyoCell 144
Myocell VT 144
Provacel 145
OTHER MESENCHYMAL CELLS 145
Prochymal 145
Tissue Repair Cells - Aastrom Bioscience 146
PANCREAS 146
IxSC-1 146
KIDNEY 147
Renal Assist Device 147
STEM CELL STORAGE 147
BIOARCHIVE STEM CELL SYSTEM 147
CCEL CELLULAR STORAGE FREEZER 148
STRUCTURE OF THE INDUSTRY 149
CYTOKINE AND GROWTH FACTOR COMPANIES 149
Table 42 COMPANIES SUPPLYING APPROVED CYTOKINE OR GROWTH FACTOR THERAPIES 149
MARKET SHARES OF CYTOKINE AND GROWTH FACTOR COMPANIES 150
Table 43 RANKINGS AND MARKET SHARES OF COMPANIES FOR CYTOKINES AND GROWTH FACTORS IN 2004 (REVENUES) 150
PRODUCTS UNDER DEVELOPMENT 150
Table 44 COMPANIES DEVELOPING GROWTH FACTOR OR CYTOKINE PRODUCTS 151
UMBILICAL CORD STEM CELL COMPANIES 151
Table 45 2004 WORLDWIDE MARKET RANKINGS FOR UMBILICAL CORD STEM CELL STORAGE COMPANIES 151
CELL THERAPY COMPANIES 152
Table 46 FOCUS OF STEM AND PROGENITOR CELL THERAPY COMPANIES 152
Table 46 (CONTINUED) 153
Table 46 (CONTINUED) 154
PATENTS 154
PATENTS (CONTINUED) 155
Table 47 U.S. PATENT APPLICATIONS FROM JANUARY 1, 2001 THROUGH SEPTEMBER 8, 2005, WITH SELECTED STEM CELL SEARCH TERMS 156
Table 48 SELECTED U.S. STEM CELL PATENTS ISSUED BETWEEN JANUARY 2002 AND SEPTEMBER 2005 157
Table 48 (CONTINUED) 158
Table 48 (CONTINUED) 159
Table 48 (CONTINUED) 160
ATTRITION 160
Table 49 DISAPPEARING NAMES IN REGENERATIVE MEDICINE 161
COMPANY PROFILES 162
AASTROM BIOSCIENCES 162
ADERANS RESEARCH INSTITUTE 162
ADVANCED CELL TECHNOLOGY 163
ADVANCED CELL THERAPEUTICS 164
AMGEN 164
ANORMED 165
ATHERSYS 165
BAXTER INTL. 166
BEFUTUR BIOTECHNOLOGIES 166
BIOHEART 167
BIOMATRIX SCIENTIFIC GROUP 168
BIOTISSUE, INC. 168
BIOTISSUE TECHNOLOGIES AG 168
BRAINSTORM CELL THERAPEUTICS 169
CELLARTIS 170
CELL BASED DELIVERY 170
CELLERANT THERAPEUTICS 171
CELLRESEARCH CORP. 171
CELLULAR DYNAMICS 172
CHEMOKINE THERAPEUTICS 172
CO.DON AG 173
CORCELL 173
CORD BLOOD AMERICA 173
CORD BLOOD REGISTRY 174
CYGENICS 174
CORDLIFE PTE, LTD./ CELL SCIENCES PTE, LTD. 174
CYTOMATRIX 175
CRYO-CELL INTL. 175
CYTHERA 176
CYTORI THERAPEUTICS 176
DENTIGENIX, INC. 177
ENCELLE 177
ENZO BIOCHEM 178
EXTENDFERTILITY 179
FIDIA FARMACEUTICI SPA 179
FREZER, INC. 179
GENZYME BIOSURGERY 180
GENVEC 181
GERON 181
HISTOSTEM 182
INTERCYTEX 182
INTERFACE BIOTECH A/S 183
ISLET TECHNOLOGY 183
ISTO TECHNOLOGIES 184
IXION BIOTECHNOLOGY 185
KALEIDOS PHARMACEUTICAL 185
JOHNSON & JOHNSON 186
LIFEBANK CRYOGENICS 186
MEDRA 187
MESOBLAST, LTD. 187
MILTENYI BIOTEC GMBH 188
MORPHOGENESIS 188
NEOSTEM 189
NEPHROS THERAPEUTICS 189
NEURALSTEM BIOPHARMACEUTICALS 190
NEURONYX 190
NOVARTIS INTERNATIONAL AG 191
NS GENE A/S 191
ODONTIS 192
ORGANOGENESIS 192
ORTEC INTL. 193
ORTHOLOGIC 193
OSIRIS THERAPEUTICS 194
PHARMA FRONTIERS 194
PHARMASTEM THERAPEUTICS 195
PLURISTEM LIFE SYSTEMS 195
PRIMEGEN BIOTECH, LLC 196
PROGENITOR CELL THERAPY 196
PRONEURON BIOTECHNOLOGIES 197
REGENERX BIOPHARMACEUTICALS 197
RENEURON 198
SANERON CCEL THERAPEUTICS, INC. 198
STEMCELLS, INC. 199
STEMCELL PHARMA, INC. 199
STEM CELL SCIENCES 200
STEM CELL THERAPEUTICS CORP. 200
STEM CELL THERAPY INTL. 201
THERMOGENESIS 202
TISSERA 202
U.S. BIODEFENSE, INC. 202
VESTA THERAPEUTICS 203
VIACELL 203
WICELL RESEARCH INSTITUTE 204
APPENDIX 205
GLOSSARY OF TERMS AND ABBREVIATIONS 205
GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED) 206
GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED) 207
GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED) 208
GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED) 209
GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED) 210
GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED) 211
GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED) 212
GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED) 213
LIST OF TABLES
Summary Table:
GLOBAL FORECAST OF REVENUES FOR STEM CELL AND CYTOKINE THERAPIES IN REGENERATIVE MEDICINE, THROUGH 2010 ($ BILLIONS)
Table 1 PERCENT OF PERSONS USING PRESCRIPTION DRUGS IN THE PAST MONTH IN THE U.S., 1999-2000
Table 2 SELECTED CYTOKINES OR GROWTH FACTORS RELEVANT TO REGENERATIVE MEDICINE
Table 3 LEADING CAUSES OF DEATH IN THE U.S., 2001
Table 4 PREVALENCE OF MEDICAL CONDITIONS IN THE U.S. WITH POTENTIAL CELL THERAPIES
Table 5 AGING OF THE U.S. POPULATION
Table 6 POPULATION OF COUNTRIES OF THE EUROPEAN UNION, 2003
Table 7 DESCENDANTS OF THE HUMAN MESENCHYMAL STEM CELL
Table 8 A PARTIAL LIST OF DISEASES TREATED USING
CORD BLOOD STEM CELLS
Table 9 DERIVATION OF BODY TISSUE TYPES FROM GERM LAYERS
Table 10 CELL TYPES DERIVED FROM EMBRYONIC STEM CELLS IN VITRO
Table 11 MARKERS OF PLURIPOTENT CELLS IN MOUSE, MAN, AND MONKEY
Table 12 EMBRYONIC STEM CELL LINES THAT MEET NIH FUNDING REQUIREMENTS, WHICH ARE AVAILABLE FOR SHIPPING
Table 13 FOOD AND DRUG ADMINISTRATION BODIES INVOLVED IN IMPLANT REGULATION
Table 14 A PARTIAL LIST OF DISEASES TREATED WITH HEMATOPOIETIC STEM CELLS
Table 15 COMMERCIAL OPPORTUNITIES FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
Table 16 APPROVED BIOPHARMACEUTICALS FOR THE REGENERATION OF BLOOD AND IMMUNE CELLS AFTER CHEMOTHERAPY
Table 17 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, THROUGH 2010 ($ MILLIONS)
Table 18 COMMERCIAL UMBILICAL CORD BLOOD STORAGE COMPANIES
Table 19 FEES CHARGED BY MAJOR UMBILICAL CORD BLOOD BANKS, 2005 ($)
Table 20 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, THROUGH 2010 ($ MILLIONS)
Table 21 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, THROUGH 2010 ($ MILLIONS)
Table 22 AQUIRED IMMONDEFICIENCY CASES REPORTED BY YEAR IN THE U.S., 1985-2003
Table 23 SIZE OF THE AIDS/HIV EPIDEMIC
Table 24 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS)
Table 25 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, THROUGH 2010 ($ MILLIONS)
Table 26 GROWTH FACTOR PRODUCTS FOR BONE HEALING
Table 27 GROWTH FACTORS DEVELOPED BUT NOT YET APPROVED FOR BONE INDICATIONS
Table 28 SPINAL FUSION DATA, U.S. 1998-2002 ($)
Table 29 NUMBER OF LOWER LEG FRACTURE, 1998-2002
Table 30 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS)
Table 31 PRODUCTS FOR REGENERATIVE CARTILAGE REPAIR
Table 32 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, THROUGH 2010 ($ MILLIONS)
Table 33 PREVALENCE OF HEART DISEASE IN U.S. ADULTS (18 YEARS AND OVER), 2002 (THOUSAND)
Table 34 DEATH RATES PER 100,000 FROM CEREBROVASCULAR DISEASE (STROKE) IN THE U.S., 1960 AND 2002
Table 35 GLOBAL PREVALENCE OF DIABETES IN EUROPE, AGES 20 TO 79, 2003 AND 2005 (THOUSANDS)
Table 36 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, THROUGH 2010 ($ MILLION)
Table 37 CYTOKINES AND GROWTH FACTORS IN REGENERATIVE MEDICINE
Table 38 LIVING BLOOD AND IMMUNE CELL THERAPEUTIC PRODUCTS IN DEVELOPMENT
Table 39 LIVING SKIN EQUIVALENTS USED THERAPEUTICALLY
Table 40 LIVING-CELL PRODUCTS USED THERAPEUTICALLY TO REPAIR CARTILAGE
Table 41 MUSCLE CELLS USED AS THERAPEUTIC PRODUCTS
Table 42 COMPANIES SUPPLYING APPROVED CYTOKINE OR GROWTH FACTOR THERAPIES
Table 43 RANKINGS AND MARKET SHARES OF COMPANIES FOR CYTOKINES AND GROWTH FACTORS IN 2004 (REVENUES)
Table 44 COMPANIES DEVELOPING GROWTH FACTOR OR CYTOKINE PRODUCTS
Table 45 2004 WORLDWIDE MARKET RANKINGS FOR UMBILICAL CORD STEM CELL STORAGE COMPANIES
Table 46 FOCUS OF STEM AND PROGENITOR CELL THERAPY COMPANIES
Table 47 U.S. PATENT APPLICATIONS FROM JANUARY 1, 2001 THROUGH SEPTEMBER 8, 2005, WITH SELECTED STEM CELL SEARCH TERMS
Table 48 SELECTED U.S. STEM CELL PATENTS ISSUED BETWEEN JANUARY 2002 AND SEPTEMBER 2005
Table 49 DISAPPEARING NAMES IN REGENERATIVE MEDICINE
LIST OF FIGURES
Summary Figure:
GLOBAL FORECAST OF REVENUES FOR STEM CELL AND CYTOKINE THERAPIES IN REGENERATIVE MEDICINE, 2003-2010 ($ BILLIONS)
Figure 1 HEMATOPOIESIS
Figure 2 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, 2003-2010 ($ MILLIONS)
Figure 3 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, 2003-2010 ($ MILLIONS)
Figure 4 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, 2003-2010 ($ MILLIONS)
Table 5 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS)
Figure 6 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, 2003-2010 ($ MILLIONS)
Figure 7 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS)
Figure 8 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, 2003-2010 ($ MILLIONS)
Figure 9 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, 2003-2010 ($ MILLION)
CMS, P&A House, Alma Road, Chesham, Bucks. HP5 3HB, UK
Tel: +44 (0)1494 771734
Fax: +44 (0)1494 778994
e-mail: jenniferc@cmsinfo.com
copyright © 2005 all rights reserved
For more information about us, visit CMSinfo.
